Rapid Selection Of Antibodies Against Membrane Targets Using Cell-Binding Assays

The development of new tools is for the down-selection of lead candidates, is bring about faster and more streamlined antibody therapeutic development. There are still challenges scientist need to face to continue progress developing antibody drugs that target membrane proteins though, such as the difficulties difficult to extract and isolate cell membrane proteins and screening against their native conformation.

Opto^® Plasma B Discovery on the Beacon^® optofluidic system accelerates the down-selection of lead candidates by enabling direct screening of plasma B cells using assays for both soluble antigens and cell membrane-bound antigens. Through this study you will see how multiple assays can be run on the same plasma B cells, reducing lead candidate selection from 8–12 weeks to just 1 day. This early characterization translates to the identification of antibody therapeutic candidates more rapidly, reducing development timelines and downstream costs.